inter-alpha-trypsin inhibitor heavy chain 5Genealiases: ITI-HC5 · PP14776
Q-omics provides the consensus-scored ITIH5 profile across patient tissues and cancer cell-line models. ITIH5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ITIH5 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ITIH5 protein abundance shows 26,482 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where ITIH5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITIH5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITIH5 survival associations across molecular data types. ITIH5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITIH5 RNA expression–survival associations across cancer types. High ITIH5 expression shows favorable associations in HNSC, SCLC, KIRC, SARC, THCA and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ITIH5 RNA expression.
This table summarizes ITIH5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ITIH5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITIH5 shows lower tumor expression in BLCA, LUAD, COAD, KIRP, LUSC and BRCA. The BLCA box plot shows higher ITIH5 RNA expression in normal versus tumor tissue (log2 FC = −4.180, t-test p < 0.001).
This table shows molecular features associated with ITIH5 in patient tissues and cancer cell lines. In patient samples, ITIH5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITIH5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
